Put Options

8 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.51 - $2.39 $39,562 - $62,618
26,200 Added 27.01%
123,200 $193,000
Q2 2024

Aug 14, 2024

SELL
$1.54 - $2.28 $4,158 - $6,155
-2,700 Reduced 2.71%
97,000 $162,000
Q1 2024

May 15, 2024

BUY
$1.3 - $3.58 $27,560 - $75,896
21,200 Added 27.01%
99,700 $239,000
Q4 2023

Feb 14, 2024

BUY
$1.0 - $1.53 $2,700 - $4,131
2,700 Added 3.56%
78,500 $120,000
Q3 2023

Nov 14, 2023

SELL
$1.06 - $2.33 $41,764 - $91,802
-39,400 Reduced 34.2%
75,800 $82,000
Q2 2023

Aug 14, 2023

BUY
$2.15 - $3.49 $166,840 - $270,824
77,600 Added 206.38%
115,200 $263,000
Q1 2023

May 15, 2023

BUY
$1.99 - $2.68 $67,660 - $91,120
34,000 Added 944.44%
37,600 $91,000
Q4 2022

Feb 14, 2023

BUY
$1.8 - $2.56 $6,480 - $9,216
3,600 New
3,600 $6,000

Others Institutions Holding LXRX

About LEXICON PHARMACEUTICALS, INC.


  • Ticker LXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 188,726,000
  • Market Cap $157M
  • Description
  • Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...
More about LXRX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.